Goodpasture's disease provides an opportunity to analyse molecular mechanisms that may underlie MHC class II associations with autoimmune disease because it is caused by autoimmunity to a defined antigen [the 230 amino acid NC1 domain of the α3 chain of type IV collagen (α3(IV)NC1)] and has strong HLA class II associations. We compared the α3(IV)NC1 peptide binding of class II molecules with strong positive (DR15) and dominant negative (DR7/1) associations using an inhibition binding assay and short synthetic peptides spanning the sequence of α3(IV)NC1. DR15 in general bound the peptides with low affinity (three of 23 < 100 nM) compared to DR1 and DR7 (12 and 10 < 100 nM respectively), and no peptide bound DR15 with much higher affinity (>10-fold) than both DR1 and DR7. Thus DR15 molecules are unlikely to increase susceptibility to Goodpasture's disease by presenting a particular α3(IV)NC1-derived peptide uniquely well and DR1/7 are unlikely to protect by their inability to present particular peptides. However DR1/7 could protect by capturing α3(IV)NC1 peptides and preventing their display bound to DR15; the binding data suggest that all the major (biochemically detectable) α3(IV)NC1 peptides presented bound to DR15 by DR15 homozygous antigen-presenting cells (APC) would bind preferentially to DR1/7 in DR15, 1/7 heterozygote APC.
Introduction
Goodpasture's disease has very striking associations with mine the antigen-derived peptides displayed to T cells (3). Very likely their peptide binding preferences also influence alleles inherited at MHC class II loci. Almost 80% of patients carry DRB1*1501, one of the alleles contributing to the DR2 immune responses to self proteins. Comparisons of MHC molecules with similar disease associations have demonspecificity, compared with 25% of control populations, giving an odds ratio for disease of 8.5. An even more striking strated similarities in both the structures of their peptide binding grooves (e.g. 4-6) and in their peptide-binding opposite influence is exerted by DR7 alleles which appear to protect from the disease even in the presence of DRB1*1501 properties (7, 8) , suggesting that disease association is a consequence of capacity to present particular peptides. (dominant protection). There are weaker positive associations with DR3 and DR4 alleles, and negative associations with Evidence that expression of class II alleles directly influences autoimmunity has been obtained in mice transgenic for HLA DR1 alleles. The associations are similar to those reported for many other autoimmune diseases and animal models of class II alleles (9,10). Exactly how MHC-determined differences in autoantigen presentation influence susceptibility to autoimmunity (reviewed in 1).
The mechanisms that account for MHC associations with autoimmunity is controversial. The major mechanisms are probably not the same in all studied examples of autoimmune autoimmunity are not known, but there is compelling evidence that it is in large part expression of the MHC molecules diseases and models of autoimmunity. For example, it is well established that susceptibility to diabetes is strongly themselves that account for the associations (e.g. see 2). MHC molecules influence immune responses to exogenous influenced by MHC class II alleles in NOD mice, but three studies of transgenic NOD mouse lines aimed at elucidatantigens because their peptide binding preferences deter-ing the mechanisms have offered support for a distinct mechanisms in each case (11-13).
Goodpasture's disease is an autoimmune cause of kidney and lung failure that affords an unparalleled opportunity to study how HLA class II molecules might influence susceptibility to an important clinical disease. The disease is unique because, as well as having well-defined very strong positive (with DR15) and dominant negative (with DR7 and DR1) HLA class II associations (1,6,14,15), the target of autoimmune attack has been narrowed down to the relatively small 230 amino acid C-terminal NC1 domain of the α3 chain of type IV collagen [α3(IV)NC1] (16,17), and the most abundant naturally processed α3(IV)NC1-derived peptides presented bound to DR15 molecules have been defined biochemically (18, 19) . Knowledge of the antigen is clearly essential for analysis of antigen-class II interactions. Knowledge of putative major naturally processed peptides is important as it identifies autoantigen-derived peptides generated by the processing machinery within human antigen-presenting cells (APC) that are available to bind available class II molecules. It also identifies the major peptides actually presented to CD4 T cells in susceptible individuals. CD4 T cells are likely to be important in Goodpasture's disease at least for provision of T cell help to potentially autoreactive T cells and possibly also for driving the characteristic crescentic pattern of glomerular injury, as has been shown in a murine model (20) . Evidence that a patient's CD4 T cells recognize α3(IV)NC1 comes from previous studies with purified and recombinant protein (21) , and from our own recent observation that a patient's T cells proliferate and produce IFN-γ to intact recombinant α3(IV)NC1 and certain peptides but not α5(IV)NC1 (unpublished data).
Here we report analysis of the α3(IV)NC1 peptide-binding preferences of three HLA-DR molecules with divergent associations with susceptibility to Goodpasture's disease. DR15b (composed the gene products of DRA and DRB1*1501), DR1 and DR7 were selected for this study because analysis of published genotype data of patients with Goodpasture's disease showed: (i) DRB1*1501 and probably 1502 are strongly associated with Goodpasture's disease (odds ratio 8.5), but DR16 alleles are not, despite also encoding the DR2 processed and presented peptides. Peptides for which no binding Strikingly, we find that DR molecules associated with strong was detected are shown on the abscissa with error bars reaching to the detection limit of the assay,~100 µM. For comparison with other dominant protection have generally much higher affinity for studies, horizontal lines are shown dividing the peptides into groups α3(IV)NC1 peptides than DR15, the DR molecule that is most with high (K i Ͻ 100 nM), intermediate (100 nM Ͼ K i Ͻ 10 µM) and strongly associated with increased susceptibility. low (K i Ͼ10 µM) affinity as proposed in (3), using the relations shown in Methods.
Methods
The peptides used in this study and method of preparing purified class II molecules are the same as described elsemurine mAb L243 (22) . The murine L cell transfectant LDR2b (23) was used because available mAb do not distinguish where (18) . HLA-DR molecules were affinity purified from detergent lysates of the cell lines LDR2b (yielding DR15b) between the two DR molecules carried by human DR15 homozygous APC. The DR7 preparation was contaminated (23), CF0996 (DR7) and HOM2 (DR1) respectively using the by DRw53 molecules at a low level: Southwood et al. have B is binding in the absence of unlabelled test peptide (the equation derives from the law of mass action). IC 50 s were shown that DRw53 contamination does not influence DR7 peptide-binding assays under conditions similar to those used determined in at least three independent experiments. Expressed as logarithms, the experimental data was normally in this study (24) , presumably because of their low level relative to that of DR7, the limiting conditions used in the distributed with SD ϭ 0.165 and the 95% confidence limits for the arithmetic means (three measurements) were Ϯ0.19. assay and the very different peptide binding characteristics of DRw53 molecules (25) .
Therefore the 95% confidence limits for measured IC 50 s (in moles) were between (mean/1.5) and (meanϫ1.5).
Peptide binding assays
Calculation of K i Peptide binding to purified class II molecules was measured using an inhibition assay based on that described by Tompkins
To use IC 50 measurements to compare the affinity of peptides for different class II molecules measured against different and Jensen (26) and fully described in (18) . The myelin basic protein peptide MBP 86-98(98A) and flu haemagglutinin reference peptides it was necessary to determine an absolute measurement of peptide class II affinity (IC 50 measurements peptide HA307-319 were selected as reference peptides because of their reported high affinity for DR15b and DR1/7 are dependent upon the experimental conditions used). When both reference peptide (P ref ) and test peptides (P i ) are used respectively (27) . As before, the concentrations of peptides [P i ] causing 50% reduction in reference peptide binding in excess of available class II, the (inhibition) dissociation constant (K i ) of the complex DR-P i is related to the measured (IC 50i ) were extracted from experimental binding data by curve fitting to functions of the form B/(1 ϩ [P i ]/IC 50i ), where IC 50 by the formula is the concentration of reference peptide and K dref is the of 24) (Fig. 1 , bottom panel), including the three peptides known to be naturally processed and presented in DR15-equilibrium dissociation constant of DR-reference peptide complexes. The K dref of *MBPP-DR15b, *HAP-DR7 and homozygous human B cells (identified in Fig. 1 with large diamond markers) (18, 19) . This is in striking contrast with *HAP-DR1 were estimated to be 16, 15 and 5 nM respectively by Hill transformation of binding measured at a DR15b molecules to which the same peptides bound with mostly intermediate (14 of 24) or low/unmeasurable affinity range of concentrations of reference peptides, and reference peptides were used at 160, 88 and 27 nM for DR15b, DR7
(seven of 24), only three peptides having high affinity (Fig. 1 , top panel). The assay conditions permitted measurement of and DR1 respectively. Therefore, for comparison purposes, K i~I C 50 /11 for DR15b inhibition assays, IC 50 /6.87 for DR7
IC 50 for peptides with IC 50 Ͻ~100 µM, so did not distinguish low-affinity binding (IC 50 Ͼ100 µM, K i Ͼ~10 µM) from assays and IC 50 /6.33 for DR1 assays.
non-binding.
Motif analysis
The results showed that DR7 had generally higher affinity for α3(IV)NC1 peptides than DR15b. In order to compare Motif analysis for DR1 and DR7 was conducted using motifs reported by Southwood et al. (24) . For DR15b we adapted a affinity for individual peptides, the logarithms of the calculated K i for binding to DR7 and DR15b were subtracted (Fig. 2 , motif we used previously, based on reported binding data top panel). Only two peptides, P7 and P11, had higher affinity (27, 28) , by weighting smaller hydrophobic residues (VILM) at for DR15b than DR7, and for neither was the difference position 1 and larger hydrophobic residues (WYF) at position substantial (~4-and~3-fold respectively). Of the three pep-4. The weighting is suggested by the reported relative sizes tides known to be generated by natural processing of intact of pockets 1 and 4 in the crystal structures of DR15b and α3(IV)NC1 within human APC (from their detection bound to DR1 (29) , and supported by our own pool sequencing data DR15b molecules of α3(IV)NC1-pulsed APC (18, 19) , one (see Processing and presentation of the Goodpasture antigen, (P17) bound DR7 with 40-fold higher affinity than to DR15b R. Phelps, PhD Thesis, University of London, 1998) and that and two had indistinguishable (P3b) or just worse (P7) affinity of other groups (Andrew Godkin, pers. commun. and 30).
for DR7 compared with DR15b. The significance of the measured differences in DR7 and Results DR15b binding affinity for presentation to α3(IV)NC1 peptides Binding of α3(IV)NC1 peptides to HLA-DR7 to T cells must depend on how α3(IV)NC1 is processed within All of the peptides bound to DR7 molecules. To permit APC, and in particular on which α3(IV)NC1 peptides are comparison with class II-peptide binding measurements made available for class II binding. So far there is little reported elsewhere, the IC 50 measurements were used to evidence of substantial HLA-associated polymorphism in the calculate inhibition dissociation constants (K i ) for each interprocessing machinery so we considered the implications of action. Horizontal bars in Fig. 1 demarcate peptides binding the binding data for α3(IV)NC1 presentation to T cells assumwith high, intermediate and low affinity. All of the peptides ing the major α3(IV)NC1 peptides we previously identified in eluates from DR15 molecules in α3(IV)NC1-pulsed DR15-bound to DR7 with intermediate (13 of 24) or good affinity (11 Fig. 4 . Identification of core DR-binding sequences in naturally processed α3(IV)NC1 peptides. The figure is organized as three vertical panels each showing the sequences of one of the three sets of naturally DR15-presented α3(IV)NC1 peptides at the top (18), over graphs of relevant affinity and motif data for DR15b, DR1 and DR7 molecules. To display affinity data in a way that allows appreciation of how the sequences of the peptides overlap, peptides are depicted as series of open circles (representing individual amino acids) on an abscissa that is the sequence of α3(IV)NC1, drawn on an ordinate log K i scale. For intuitive simplicity peptides with higher affinity (lower K i ) are drawn higher on the ordinate axis. Motif data is superimposed in the form of vertical bars marking on the abscissa the proposed P1 residue (that locates in pocket 1 of the class II molecules). The height of the bars indicates how well the proposed core sequences matches the motif. Motifs used are described in Methods. Likely core-binding sequences inferred from the data are identified by underlines in the abscissa labels.
homozygous APC are processed and available for class II 1, middle panel). Comparison of the affinity of individual peptides for DR1 and DR15b (Fig. 1, bottom panel) found binding in DR7 APC. The results suggest that, barring as yet that two peptides, P11 and P14, had convincingly higher unrecognized HLA-linked processing polymorphism, at least affinity for DR15b than DR1 and only for P11 was the difference two and possibly all three of the major (biochemically detectsubstantial (13-fold). Of the three naturally processed able) naturally processed and presented α3(IV)NC1 peptides α3(IV)NC1 peptides, one (P3b) bound DR1 with 10-fold higher displayed bound to DR15b by DR15b-homozygous APC in affinity than to DR15b, and two had indistinguishable affinity disease-susceptible individuals, would also be presented for DR15b and DR1. Therefore, as for DR7, all the major bound to DR7 in disease-protected individuals.
naturally processed and presented α3(IV)NC1 peptides disThus the highly disease-protective class II molecule, DR7, played bound to DR15b by DR15b-homozygous APC in has high affinity for most α3(IV)NC1 peptides, both compared disease-susceptible individuals would also be expected to to HLA peptide interactions in general and compared with be presented bound to DR1 in disease-protected individuals. the affinity of DR15b for the same peptides. To see if this
It appeared that DR1 and DR7 had very similar peptide feature was common to different class II molecules with binding characteristics relative to DR15b, so we compared similar protective disease associations we went on to examine them with one another (Fig. 3 ). There were striking differences binding to HLA-DR1.
(Ͼ10-fold) for most (15 of 24) of the peptides, so DR1 and DR7 do not have a similar disease association simply because Binding of α3(IV)NC1 peptides to HLA-DR1 they are closely related class II molecules. Therefore the Like DR7, DR1 bound most of the peptides with high (12 of results confirmed that generally high affinity for α3(IV)NC1 24) or intermediate (nine of 24) affinity; only three peptides peptides was a consistent feature of disease-protective class II molecules in Goodpasture's disease. either did not bind or bound with unmeasurable affinity (Fig. contained within the slightly longer common core sequence of the previously identified naturally DR15b-presented peptides from this region of α3(IV)NC1.
The second set of naturally presented α3(IV)NC1 peptides was overlapped by four synthetic peptides (middle panel of Fig. 4) . The affinities for DR15b of the available synthetic peptides were very similar and most contained several DR15b motifs, so it was not possible to localize a single core-binding sequence. The sequences of the naturally presented peptides suggests FCNVNDVCNF to be the favored DR15 core-binding sequence. Two DR1 and three DR7 core-binding sequences The striking observation is that class II molecules associated with protection from Goodpasture's disease have higher affinsequences becomes very important when using peptidebinding data to consider how autoantigen-derived peptides ity for most α3(IV)NC1 peptides, including those known to be naturally processed in human B cells. The results have might bind to different class II molecules in APC expressing several different HLA molecules or to identify possible T cell important implications for the mechanism by which class II alleles influence susceptibility to Goodpasture's disease and epitopes. We employed two techniques to gain an indication of the likely core binding sequences in the α3(IV)NC1 peptides in particular the mechanism of HLA-associated dominant protection in this disease. known to be generated by processing within APC: (i) we compared the DR-binding affinities of peptides with overMechanism by which HLA class II alleles increase susceptilapping sequences and (ii) we applied published peptidebility to Goodpasture' s disease binding motifs (Fig. 4) .
Five peptides were available with sequences overlapping The data suggest that DR15b cannot be associated with increased susceptibility to Goodpasture's disease because it the first set of putative naturally presented peptides (shown at top of left panel of Fig. 4 ). They were P3a, P3b P4, P5 and has high affinity for particular α3(IV)NC1 peptides. With the exception of peptide 11, all of the Goodpasture antigen a truncation analogue of P3b with the sequence GTVPLYSGFSFL. The affinity of the peptides for DR15b, DR1 peptides studied bound as well or better to DR1 or DR7, which have the opposite association with the disease. Indeed, and DR7 is shown as log(calculated K i ) in Fig. 4 (lefthand panel) (K i were calculated from measured IC 50 s). To the data predict that individuals carrying DR1 or DR7 would present almost any α3(IV)NC1 peptide that could be appreciate how the sequences of the peptides overlap, each peptide is depicted by a series of open circles (representing generated by processing just as efficiently as individuals carrying DR15, including all those known to be generated by individual amino acids) on an abscissa that is the sequence of α3(IV)NC1. Peptides drawn higher in the three graphs have α3(IV)NC1 processing in human B cells. This observation is unlikely to be an artifact of the represhigher affinity for the respective class II molecules. The analysis suggested that the core sequence by which the entation of α3(IV)NC1 by a set of synthetic peptides because the panel of peptides spanned the entire sequence of peptides bound to the class II molecules was VPLYSGFSFL (underlined on abscissa) for the DR15b molecule, and α3(IV)NC1 and adjacent peptides overlapped by at least 10 amino acids, the length of the class II peptide-binding groove, FSFLFVQGNQ for DR1 and DR7 molecules. The core DR15b-binding sequence of the synthetic peptides was entirely thereby including all the possible class II core-binding sequences in α3(IV)NC1 at least once. One peptide, P11, did identify numerous other class II molecules that like DR15b were unable to present some or all of these peptides. Morehave higher affinity for DR15b than for DR1 or DR7, but at least two factors are strongly against a role for this peptide over, central tolerance to α3(IV)NC1 is far from complete as the peripheral blood T cells of healthy individuals proliferate in the autoimmune responses to α3(IV)NC1. (i) P11 binds better to DR1 than to DR7 and better to DR7 than to DR15, when incubated with purified native α3(IV)NC1 (35), recombinant α3(IV)NC1 (36) and α3(IV)NC1 peptides (our unwhereas the order of association from negative to positive is DR7, DR1 and DR15. (ii) P11 is not biochemically detectable published observations). bound to DR15 molecules purified from α3(IV)NC1-pulsed
Mechanism of dominant protection DR15-homozygous APC, whereas peptides with much lower DR15 affinity are. We have recently used murine T cell clones Dominant protection has been reported for many autoimmune diseases including diabetes and rheumatoid arthritis (37,38) specific for P11 to interrogate peptide mixtures eluted from DR15 molecules from α3(IV)NC1-pulsed APC with much as well as Goodpasture's disease. Three major mechanisms are supported by experimental results; two suggest protective higher sensitivity (10-fold at least) and still not detected P11 peptides. Very likely P11 is not generated or rapidly destroyed class II molecules influence the T cell repertoire to autoantigens, either by driving central deletion or promoting peripheral during α3(IV)NC1 processing in human B cells. Thus efficient presentation of α3(IV)NC1 peptides by the DR15 molecule tolerance of some form; the third proposes that protective class II molecules capture autoantigen-derived peptides precannot alone account for the association of the molecule with increased susceptibility to Goodpasture's disease.
venting their display bound to class II molecules that restrict pathogenic T cells. High affinity for α3(IV)NC1 peptides was The finding is in contrast to immune responses to exogenous antigens, where efficient presentation appears to engender a feature of both DR molecules associated with dominant protection from Goodpasture's disease. So whilst not directly stronger immune responses (3,31,32), but compatible with more complex models for the relationship between presentainforming about the mechanism by which DR7 and DR1 protect from Goodpasture's disease, the results are in striking tion of autoantigen-derived peptides and propensity for autoimmunity (33, 34) . For example, a peptide such as P11 that accord with epitope capture as a mechanism for dominant protection in this disease. has very high affinity for DR15b, but is not usually presented because of processing constraints, could be presented under
The epitope capture hypothesis proposes that the combination of class II molecules in the peptide-loading compartments conditions that induce autoimmune disease (a cryptic antigen). Alternatively, the data identified seven α3(IV)NC1 pepof APC influences the peptides that become bound to each. The concept is illustrated in Fig. 5 . Dominant protection is tides (P2, P3a, P5, P13, P16, P21 and P23) that bound to DR15b with low affinity (K i Ͼ 1ϫ10 -5 M) at best, but this accounted for by proposing that the peptides recognized bound to disease-associated class II molecules by autoreaccould still be high enough to support autoimmune responses comparable to those reported for an encephalolitogenic tive T cells are displayed instead bound to protective class II molecules in APC expressing both types of class II molecule. peptide in the generation of experimental autoimmune encephalomyelitis (34) . However, we do not favor these For autoimmunity to be averted it would also be necessary that tolerance be securely established to the autoantigenpeptides as candidate disease-associated peptides in Goodpasture's disease because it is difficult to reconcile derived peptides presented on the disease-protective class II molecules, as might be predicted for efficiently presented the strong association of Goodpasture's disease with DRB1*1501/2, but not other related DR2 alleles, if the self-peptides. The mechanism was first proposed by Werdelin (39) and suggested by Nepom et al. (40) to explain the defining feature of disease-associated class II molecules is just low-affinity binding of α3(IV)NC1 peptides. Three of the protective effective of DR2 in diabetes mellitus. Powerful evidence that epitope capture can influence immune seven low DR15b-binding peptides did not bind detectably to DR1. Thus it seems likely that a wider study of the many responses has been obtained in NOD/BALB/c F1 mice (12), and the process has been demonstrated biochemically (41 to be forthcoming until the targets of autoimmune attack have been identified with certainty. References In Goodpasture's disease, epitope capture would be favored if DR1/7 bound core sequences in α3(IV)NC1 close to
